###
中国临床研究英文版:2026,39(8):1176-1180
本文二维码信息
码上扫一扫!
LOXL2、NRG1在HER2阳性胃癌患者中的表达特征及对靶向治疗耐药的预测价值
(1. 北京航天总医院肿瘤科, 北京 100076;2. 石家庄市人民医院, 河北 石家庄 050011;3. 北京中医药大学东直门医院, 北京 101121)
Expression characteristics of LOXL2,NRG1 and their predictive value for targeted therapy resistance in HER2-positive gastric cancer patients
摘要
本文已被:浏览 202次   下载 235次
Received:November 12, 2025   Published Online:August 25, 2026
中文摘要: 目的 探讨赖氨酰氧化酶样蛋白2(LOXL2)和神经调节蛋白1(NRG1)在人表皮生长因子受体2(HER2)阳性胃癌中的表达特征,分析其与患者临床病理特征的相关性,并评估其对靶向治疗耐药的预测价值。方法 回顾性选取北京航天总医院2022年1月至2025年1月收治的HER2阳性胃癌患者156例,患者均于术后行曲妥珠单抗联合化疗,并于接受曲妥珠单抗联合化疗方案第9 周(即3 个周期后)进行首次疗效评估,治疗后首次疗效评估为疾病进展(PD)或疾病稳定(SD)持续时间<6个月的患者为耐药组(62例),否则为非耐药组(94例)。记录患者临床资料,检测患者血清LOXL2、NRG1 水平。采用多因素logistic 回归分析HER2 阳性胃癌患者靶向治疗耐药的影响因素,并绘制受试者工作特征(ROC)曲线评估LOXL2 和NRG1 水平对耐药的预测价值。结果 耐药组TNM 分期Ⅲ~Ⅳ期、低分化、淋巴结转移、弥漫型比例均高于非耐药组(P<0.05),LOXL2水平[(94.11±13.17)ng/mL vs(78.53±11.23)ng/mL,t=7.912,P<0.01]、NRG1 水平[(23.51±4.20)ng/mL vs(19.01±2.80)ng/mL,t=8.034,P<0.01]均高于非耐药组。多因素logistic 回归分析显示,中/高分化(OR=0.308,95%CI:0.098~0.972)为靶向治疗耐药的保护因素,LOXL2水平高(OR=1.118,95%CI:1.071~1.166)及NRG1水平高(OR=1.473,95%CI:1.267~1.711)均为靶向治疗耐药的独立危险因素(P<0.05)。LOXL2、NRG1 水平单独及两项指标联合评估HER2 阳性胃癌患者靶向治疗耐药的曲线下面积(AUC)分别为0.817、0.811、0.887。结论 HER2阳性胃癌患者LOXL2、NRG1 水平与TNM 分期、淋巴结转移、Lauren 分型、分化程度相关,LOXL2、NRG1 可辅助预测HER2阳性胃癌靶向治疗耐药情况,为临床治疗提供参考。
Abstract:Objective To explore the expression characteristics of lysyl oxidase-like protein 2(LOXL2)and neuregulin-1(NRG1)in human epidermal growth factor receptor 2(HER2)-positive gastric cancer,analyze their correlations with the clinicopathological characteristics of patients,and evaluate their predictive value for targeted therapy resistance. Methods A total of 156 HER2-positive gastric cancer patients admitted to Beijing Aerospace General Hospital from January 2022 to January 2025 were retrospectively selected. All patients received postoperative targeted therapy with trastuzumab combined with chemotherapy. Patients underwent the first efficacy evaluation at week 9 of trastuzumab combined with chemotherapy(after 3 cycles of treatment). Patients whose first post - treatment efficacy evaluation showed disease progression(PD)or stable disease(SD)for less than 6 months were classified as the drug-resistant group(62 cases),while the others were classified as the non-drug-resistant group(94 cases). The clinical data of the patients were recorded,and the serum levels of LOXL2 and NRG1 were detected. Multivariable logistic regression analysis was used to identify the influencing factors for resistance to targeted therapy in HER2-positive gastric cancer patients,and receiver operating characteristic(ROC)curves were drawn to evaluate the predictive value of LOXL2 and NRG1 levels for this resistance. Results The drug-resistant group had higher proportions of TNM stages Ⅲ-Ⅳ,poorly differentiated,lymph node metastasis,and diffuse type compared to the non-drug-resistant group(P<0.05). LOXL2 levels[(94.11±13.17)ng/mL vs(78.53±11.23)ng/mL,t=7.912,P<0.01]and NRG1 levels[(23.51±4.20)ng/mL vs(19.01±2.80)ng/mL,t=8.034,P<0.01]were both higher than those in the non-drug-resistant group. Multivariable logistic regression analysis revealed that moderate/well differentiated (OR=0.308,95% CI:0.098- 0.972)was a protective factor against targeted therapy resistance. Elevated LOXL2(OR=1.118,95%CI:1.071-1.166)and elevated NRG1(OR=1.473,95%CI:1.267-1.711)were independent risk factors for resistance to targeted therapy(P<0.05).The areas under the ROC curves(AUC)for LOXL2,NRG1,and the combination of the two for predicting targeted therapy resistance in HER2 - positive gastric cancer patients were 0.817,0.811,and 0.887,respectively. Conclusion The levels of LOXL2 and NRG1 in HER2-positive gastric cancer patients are correlated with TNM stage,lymph node metastasis,Lauren classification,and differentiation degree. LOXL2 and NRG1 can help predict resistance to targeted therapy in HER2-positive gastric cancer,providing a reference for clinical treatment.
文章编号:     中图分类号:R735.2    文献标志码:A
基金项目:
引用文本:


Scan with WeChat

Scan with WeChat